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NOTABLE STUDENT WORKS*
Human Gene Therapy: Application,
Ethics and Regulation
I. Introduction
On September 14, 1990, Drs. R. Michael Blaese, W. French
Anderson' and Kenneth W. Culver3 opened the door on a new age of
medical treatment when they injected a four-year-old girl who suf-
fers from adenosine deaminase deficiency (ADA)," a rare genetic
disorder, with blood cells containing genetic material designed to
correct her genetic disease. The child is scheduled to return for
monthly treatments for two years following the procedure,5 but it is
* These student-written articles were chosen anonymously by the Notes Editor.
1. Chief of the National Cancer Institute's Cellular Immunology Section,
2. Chief of the National Heart, Lung and Blood Institute's Laboratory of Molecular
Hematology.
3. Senior Clinical Investigator at the National Cancer Institute.
4. The disease is caused by a lack of the ADA gene, which creates an enzyme that
removes dangerous metabolic byproduct from the body. If the byproducts are not removed,
they will break down the immune system. The disease is similar to the disease that affected a
Texas boy who was confined to a plastic bubble to protect him from infection. The girl in the
study has not been confined to a bubble because she was able to receive injections of a syn-
thetic version of the enzyme. Natlie Angier, Girl, 4, Becomes First Human to Receive Engi-
neered Genes, N.Y. TIMES, Sept. 15, 1990, at Al.
5. Virginia Baskerville, Human Gene Therapy Becomes a Reality, NIH OBSERVER, Vol.
1, No. 6, at 3 (Nov./Dec. 1990) [hereinafter Human Gene Therapy Becomes Reality]. The
first official reports of the preliminary findings from the study were submitted to the FDA on
December 13, 1990. These preliminary findings indicate that the genetic material injected into
the patient is functioning as expected and that the patient's immune system may even be able
to fight off a common bacteria. Natalie Angier, Gene-Treated Girl Is Raising Hopes, N.Y.
TIMES, Dec. 14, 1990, at A24. In addition, the only side effect that the patient has experienced
came after her third monthly treatment when her cheeks flushed and her temperature rose 0.5
degrees C. Virginia Baskerville, Progress Beautiful in First Gene Trial, NIH OBSERVER, Vol.
2, No. 1, at I (Jan./Feb. 1991).
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the hope of the doctors that the new genetic material injected into
the girl's blood will begin to produce copies of the ADA gene and, in
so doing, create a functioning immune system.' This experiment
marks the first time that doctors have attempted to combat a genetic
disease in humans through the use of gene therapy. 7 As scientists
learn more about the human genome8 and the genetic basis of dis-
ease, the number of applications for this type of therapy will grow.9
Researchers already have announced the discovery of the genetic ori-
gins of diseases such as sickle cell anemia, 10 cystic fibrosis," and os-
teoarthritis.' 2  Recent studies also indicate that diabetes, 3
Alzheimer's disease,' 4 and all types of tumors' 5 have a genetic basis.
In addition, on January 29, 1991, Dr. Steven A. Rosenberg'"
performed gene therapy on two patients suffering from metastatic
melanoma, a lethal type of skin cancer. 7 The process used in the
melanoma patients was similar to that used in the patient with ADA
except that the gene injected in the cancer study is designed to pro-
duce a tumor-destroying enzyme.' 8 Recently, Dr. Rosenberg began a
6. Larry Thompson, Human Gene Therapy Debuts at NilI, WASH. POST, Sept. 15,
1990, at Al.
7. Angier, supra note 4, at AI; see also Thompson, supra note 6, at AI.
8. The genome is the term used to refer to the complete set of hereditary factors con-
tained in the chromosomes. DORLAND'S ILLUSTRATED MEDICAL DICTIONARY (26th ed. 1981).
9. Dr. Blaese believes that human gene therapy will develop to the point at which physi-
cians will keep genetic material in an office refrigerator, and the infusion process will be con-
ducted in the doctor's office. Blaese admits that this is a long way off, but he is confident that
his vision will become a reality in the next century. Human Gene Therapy Becomes Reality,
supra note 5, at 6.
As of January 1992, not quite a year and a half since the first gene therapy trial, eleven
more trials have been approved by the NIH and seven more are under consideration. Robin
Herman, Gene Therapy Is No Longer a Rarity, WASH. POST, Jan. 21, 1992, at 7. In addition,
the NIH and the FDA recently cleared the way for the first commercially run clinical trial
using gene therapy. The trial will be conducted by targeted Genetic:s Corporation and will test
the application of human gene therapy in AIDS patients. Andrew Pollack, Gene Therapy Gets
the Go-Ahead, N.Y. TIMES, Feb. 14, 1992, at Dl.
10. W. French Anderson and John C. Fletcher, Gene Therapy In Human Beings: When
Is It Ethical To Begin?, 303 NEW ENG. J. MED. 1293 (1980).
11. Natalie Angier, Flawed 2-in-I Protein Causes Cystic Fibrosis, N.Y. TIMES, Feb. 26,
1991, at C3; see also Jean Seligmann, Curing Cystic Fibrosis?, NEWSWEEK, Oct. 1, 1990, at
64.
12. Osteoarthritis is the most common form of arthritis. Elizabeth Rosenthal, Genetic
Link Suggested in One Form of Arthritis, N.Y. TIMES, Sept. 5, 1990, at A18.
13. Gains Cited in Genetic Research on Diabetes, N.Y. TIMES, Feb. 15, 1991, at A17.
14. Gina Kolata, Alzheimer's Researchers Close in on Causes, N.Y. TIMEs, Feb. 26,
1991, at Cl.
15. Natalia Angler, Gene That Checks Cell Growth May Be Key to Many Cancers,
N.Y. TIMES, April 23, 1991, at CI.
16. Chief of the National Cancer Institute's Surgery Branch.
17. Natalie Angier, For First Time, Gene Therapy Is Tested on Cancer Patients, N.Y.
TIMES, Jan. 30, 1991, at Al. Dr. Rosenberg's study is the first use of gene therapy in patients
with cancer.
18. Id. The cells are called tumor-infiltrating lymphocytes (TIL) and are created using
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second experimental procedure to combat malignant melanoma.19 In
this new procedure, Dr. Rosenberg removes cells from the patient's
tumors, adds genes from a naturally occurring anti-tumor toxin,2 n
and then injects the cells back into the patient. After three weeks,
whit blood cells, or lymphocytes, are removed from the area of the
tumor. These modified white blood cells, believed to be the body's
most potent tumor fighting agent, are duplicated in the laboratory
and then injected into the patient.2"
Gene therapy is just one of the possible applications of genetic
engineering or biotechnology, the terms by which the human altera-
tion of deoxyribonucleic acid (DNA) 22 have come to be known.
Other applications of this technology range from the production of
certain types of drugs to the creation of plants and animals with
specific characteristics. 23 All of these applications offer great promise
and benefits for mankind; yet, many observers find this new technol-
ogy ethically troubling, especially when the technology is applied to
human beings. One need not imagine a Brave New World or a
Frankenstein to see the potential for abuse of genetic engineering.
This Article will examine the process of genetic engineering, some of-
the ethical objections to the process, and the present system of gov-
ernment regulation, and will attempt to show how the governmental
regulation could be improved. The focus will be on the application of
genetic engineering to human beings and the specific ethical
problems that arise as human beings become better able to apply
this new technology to themselves. The focus is narrow and other
areas, such as biotechnology in agriculture and industry, will not be
addressed. 4
white blood cells that have migrated from other parts of the body to fight the tumor. These
cells are removed from the patient and then altered in the laboratory to enable them to target
and destroy the tumor. Baskerville, supra note 5, at 1.
19. Gina Kolata, Cell Immunization Tested for Melanoma, N.Y. TIMEs, Oct. 9, 1991,
at C14.
20. The hormone is called tumor necrosis factor (TNF). Department of Health and
Human Services, Press Release (Oct. 8, 1991).
21. Susan Jenks, Attempts Made to 'Immunize" Patients Against Their Cancers, J.
NAT'L CANCER INST., Nov. 6, 1991, at 1532.
22. DNA is the biological molecule that determines the inherited characteristics of every
living cell. Glossary of Biotechnology Terms, I HIGH TECH. LAW J. 253 (1987).
23. The drugs insulin and interferon have been genetically engineered in the laboratory;
plants have been made less susceptible to the cold through genetic alteration, and animals have
been created with human immune systems.
24. Industrial areas in which genetic engineering may prove useful are chemistry, energy
production, and metallurgy. Bernard Talbot, Introduction to Recombinant DNA Research,
Development and Evolution of the NIH Guidelines and Proposed Legislation, 12 U. TOL. L.R.
817 (1981).
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11. Historical Background
Man has been attempting to manipulate genetics to his advan-
tage for centuries. Hybridization of plants, selective breeding of ani-
mals, and fermentation are all examples of simple genetic manipula-
tion. Human beings have even altered their own gene pool through
the use of conventional medicines and practiced eugenics by restrict-
ing marriages between certain people, such as first cousins.1 5 What
then can be so terribly troubling about modern genetic engineering?
The answer to this question may be both as simple and as complex
as the process of genetic manipulation itself.
The historical basis for modern genetic theory begins with Gre-
gor Mendel's26 work with heredity and Charles Darwin's27 theory of
natural selection.28 The foundations of modern biotechnology were
laid out in 1953 when Crick and Watson29 described the structure of
DNA. During the 1960s, researchers began investigating, or decod-
ing, the structure of proteins such as DNA. Finally, in 1973, two
scienti'sts at Stanford University, Cohen and Boyer, developed a pro-
cess for cutting sections from DNA and inserting a different piece of
DNA into the gap.30 This process, called "recombination," allowed
the researchers to create new proteins. The mere account of the his-
torical development of recombinant DNA technology belies the bio-
logical importance of this new technique, for DNA is "sometimes
called the 'master molecule of life' since almost all living things -
including plants, animals and bacteria - possess it."3
Cells form the basic components of an organism and, even
though each cell has a similar structure, it performs a specific and
25. James F. Keenan, What is Morally New in Genetic Manipulation?, I HUM. GENE
THERAPY 289 (1990).
26. Mendel was a German monk who postulated the existence of genes in 1865 based on
his work with the hereditary traits of peas. Scientists have recently discovered that the parent
from whom a gene is inherited may be a critical factor in the occurrence of genetic disease.
Such a finding is a significant exception to Mendel's theory of heredity which espoused the
belief that genes were equivalent whether they were inherited from the male or female. Gina
Kolata, Biologists Stumble Across New Pattern of Inheritance, N.Y. TIMES, July 16, 1991, at
Cl.
27. English naturalist, 1809-82.
28. John C. Fletcher, Moral Problems and Ethical Issues in Prospective Human Gene
Therapy, 69 VA. L. REV. 515 (1983).
29. Francis Crick was a young American scientist who hac not yet received his Ph.D.,
and James Watson was a twenty-four year old English scientist. The events surrounding the
discovery of the structure of DNA are described by Watson in hi:; book Double Helix. Judith
Areen, Regulating Human Gene Therapy, 88 W. VA. L. REV. 153 (1985).
30. William H. Von Ochsen, Regulating Genetic Engineering in an Era of Judicial Def-
erence: A Proper Balance of Federal Powers, 40 ADMIN. L.J. 30.3 (1988).
31. PRESIDENT'S COMMISSION ON THE ETHICAL ASPECTS OF GENETIC ENGINEERING:
SPLICING LIFE, at I1-1 (1983) [hereinafter SPLICING LIFE].
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quite different function. In the nucleus of each cell are structures
called chromosomes that store and transmit genetic information.
3 2
These chromosomes come in pairs,3 3 and the number of chromo-
somes present in a cell determines whether it is a germ cell (the
reproductive cells - sperm or egg - which contain only one chro-
mosome from each pair) or a somatic cell (the body cells which con-
tain a full complement of chromosomes)."' Each chromosome is
composed of a long strand of DNA, which in turn is "made up of
chemicals called nucleotides, consisting of one small sugar molecule,
one phosphate group, and one of four nitrogenous bases, which can
be thought of as the four letters of the genetic alphabet (A, G, T,
and C)." 35
In the model proposed by Crick and Watson, the structure of
the DNA appears as "two strings of nucleotides that are lined up
next to each other like the sides of a zipper - the phosphates and
sugars forming the ribbons and the nitrogenous bases acting like the
interlocking teeth of the zipper."3 6 The order of the nucleotide bases
determines the genetic code of a particular piece of DNA and thus
specifies the function of the cell." In each chromosome, the genetic
code is broken down into units or segments called genes.3 " Each gene
contains an average of 1,000 pairs of nitrogenous bases and has the
specific information to manufacture one specific protein.3 9 Proteins
are made up of amino acids, and amino acids, in turn, are composed
of three nucleotides. 0 The President's Commission on Genetic Engi-
neering likened this process to letters forming a word, with the nu-
cleotides acting as the letters and the amino acid as the word."1
The genetic information in the nucleus is "read" and trans-
ferred to a unique messenger ribonucleic acid (mRNA) molecule,
which carries the information to the cell's cytoplasm, where the
32. "Chromosome" is from Greek - "Chromo" for colored and "some" for body. SHER-
MAN ELIAS AND GEORGE J. ANNAS. REPRODUCTIVE GENETICS AND THE LAW (1987).
33. Humans have 46 or 23 pairs of chromosomes. Of these 23 pairs, the male and fe-
male have 22 identical sets, which are called autosomes, and one pair - the sex chromosome
- that determines the sex of the individual. In females the sex chromosomes are both x chro-
mosomes, while in the male there is one x and one y chromosome. Id. at 6-7.
34. Id.; see also SPLICING LIFE, supra note 31, at 11-2.
35. Elias and Annas, supra note 32, at I. A stands for adenine, T for thymine, G for
guanine, and C for cytosine. Adrienne Naumann, Federal Regulation of Recombinant DNA
Technology: Time for Change, I HIGH TECH. LJ. 61 (1986).
36. SPLICING LIFE, supra note 31, at 11-3.
37. SPLICING LIFE, supra note 31, at 11-3.
38. SPLICING LIFE, supra note 31, at 11-3.
39. Naumann, supra note 35, at 62; see also SPLICING LIFE, supra note 31, at 11-3.
40. SPLICING LIFE, supra note 31, at 11-3.
41. SPLICING LIFE, supra note 31, at 11-3.
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amino acids and proteins are produced.42 Proteins make up the struc-
tural, regulatory and metabolic elements of the cell; therefore, alter-
ing the genetic information transmitted by the RNA can have a dra-
matic effect on the cell.43 Changes occasionally occur in the sequence
of the nucleotide bases. These changes can be due to either the influ-
ence of an outside organism, a virus for example, or the failure of
the cell to properly replicate the genetic information when it di-
vides.44 In either case, these changes are called mutations if they
occur in the active portion of the genetic material. 4 5 Small mutations
can be insignificant; on the other hand, even seemingly minor
changes may result in disease.4" Mutations that are passed on to fu-
ture generations are called genetic diseases.
47
Humans entered the field of internal genetic alteration in the
1970s as a result of the work of Boyer and Cohen, two researchers at
Stanford University. Boyer discovered that fragments could be bro-
ken from the DNA chain and then reattached to the chain or at-
tached to each other in different ways to create an entirely new
DNA chain. 48 The resulting product is called recombinant DNA
(rDNA). The key to breaking apart DNA was the discovery of re-
striction enzymes, substances found in bacteria that enable the bac-
teria to protect itself from viruses by breaking down the virus'
DNA.4 9 Using this cut-and-splice technique, Cohen took a piece of
DNA from an African frog and inserted it into a plasmid.50 When
the plasmid divided, it replicated both the rDNA plasmid cells and
42. Naumann, supra note 35, at 62-63.
43. All cells contain basically the same genetic material in their nuclei, but only a small
portion of this genetic information is active. Thus, the specialized nature of the cell derives
from the active portion of the genetic material in the cell. SPLICINc LIFE, supra note 31, at If-
4.
44. SPLICING LIFE, supra note 31, at 11-4-5.
45. SPLICING LIFE, supra note 31, at 11-4.
46. Sickle cell anemia, in which "a change in the sixth triplet of the gene for hemoglobin
B-chains from CTT to CAT results in a coding for a valine instead of glutamic acid in the
sixth amino acid position," is an example of a minor change that results in disease. ELIAS &
ANNAS, supra note 32, at 6.
47. There are three simple or Mendelian patterns of inheritance for mutant genes: 1)
autosomal dominant; 2) autosomal recessive; and 3) sex-linked. Regardless of the method of
transfer, the incidence of many Mendelian disorders is very rare - perhaps only one per
10,000 to 50,000 births. Taken in the aggregate, however, Mendelian disorders affect about
I % of the babies born in the world and, in certain high-risk families, the chance of disease
may range from 25% to 50% depending on mode of inheritance. ELIAS & ANNAS, supra note
32, at 25-26.
48. Von Ochsen, supra, note 30, at 303.
49. Tie number of restriction enzymes presently identified allow the breaking apart of
DNA at any given sequence of nucleotides. SPLICING LIFE, supra note 31, at 11-6, 7.
50. A plasmid is a circular, double-stranded piece of DNA found in bacteria cells that is
able to divide apart from the cell's chromosomes. Von Ochsen, supra note 30, at 308.
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the frog DNA.51 The term for the entire process of reproducing a
specific piece of DNA is called cloning.52 Through the use of cloning
on a large scale, it is possible to produce a quantity of a particular
protein that is useful to research, medicine and/or industry. 53
The beneficial application of this technology can clearly be seen
in the use of recombinant DNA techniques to produce medicines.
The Food and Drug Administration (FDA) has already licensed va-
rious genetically engineered drugs, including "a vaccine against hep-
atitis B, a kind of monoclonal antibody that increases the success of
kidney transplants, an enzyme that dissolves blood clots, gene-spliced
human insulin, and a class of proteins, called interferons, that regu-
late the response of cells to viral infections and cancer prolifera-
tion."54 But, as the recently begun human gene therapy trials clearly
demonstrate, genetic engineering has far greater medical potential
than the mere production of drugs.
The term gene therapy is used to describe the introduction of a
normally functioning gene into a human suffering from a genetic de-
fect or disease in an attempt to cure the defect or disease. 55 The
application of this therapy can take place in either the somatic cells
or the germ cells of the patient. The key difference between these
two types of gene therapy is that alterations to the somatic cells will
affect only the patient in question, while-gene therapy to correct a
defect in the germ cells will pass on the corrected gene to future
generations. 5 Both of the trials presently being conducted in humans
employ somatic cell gene therapy and, to date, there have been no
attempts to use germ cell therapy in humans. 57 Even so, the possibil-
ity of altering future generations' genetic make-up has concerned
some ethicists and theologians. In addition, as human beings become
more advanced in the application of biotechnology, the possibility of
51. Von Ochsen, supra note 30, at 308.
52. Naumann, supra note 35, at 63.
53. Robert F. Baker and Wendy G. Clough, The Technical Uses and Methodology of
Recombinant DNA, 51 S. CAL. L. REV. 1009 (1978).
54. Von Ochsen, supra note 30, at 310. Genetic engineering of monoclonal antibodies
has received considerable attention in recent months. In February, the New York Times re-
ported on a study appearing in The New England Journal of Medicine on the use of
monoclonal antibodies to combat the effects of septic shock. Natalie Angier, Drug Cuts Deaths
Tied to Infection, N.Y. TIMEs, Feb. 13, 1991, at Al. For a more general discussion of geneti-
cally engineered monoclonal antibodies, see Lawrence M. Fisher, Biologists Re-Engineer An-
tibodies, N.Y. TIMES, Mar. 5, 1991, at Cl.
55. SPLICING LIFE, supra note 31, at 11-16.
56. SPLICING LIFE, supra note 31, at 1I-16-20.
57. Experiments using germ-line therapy have been performed in animals, but the gen-
eral opinion in the scientific community is that any human application is, at present, only a
very distant possibility.
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enhancement genetic engineering5" and eugenic genetic engineering59
become' more real. Thus, we are at the very beginning of the direct
application of genetic manipulation to human beings - the point
where the line between science and technology begins to blur. This is
also the point at which human beings should re-evaluate the relation-
ships among the science/technology of genetic manipulation, the eth-
ical problems created by the application of the technology to
humans, and the law regulating genetic manipulation before moving
on to the next level of human gene therapy.
III. Ethical Concerns
Any analysis of the ethical concerns raised by genetic engineer-
ing must begin with the very basic but highly complex concept of
what is "human" and how the greater understanding of the processes
that make us function affects our concept of humanity. There can be
no question that "[b]iology, including genetics, is particularly impor-
tant because it is the science . . . [that] . . .speaks to the funda-
mental nature of human beings." ' 0 The genetic code is the blueprint
that determines how each human life is to proceed. As we learn
more about the present and potential powers of genetic engineering,
we cannot help but think more about the nature, meaning, and value
of human life. 1 Thus, it is little wonder that:
[T]he deepest source of our uneasiness about genetic engineer-
ing lies in a pervasive sense that there is something sacred about
the remarkable process by which the order and intelligibility
proper to all life are literally given flesh in the genetic code, and
therefore, there is something impious about manipulating ge-
netic material.
6 2
This basic argument is advanced both by theologians, who believe
that the genetic code is God's work and that humans who attempt to
manipulate genetics are trespassing on God's domain, and by secular
58. Enhancement genetic engineering is the process of inserting a gene into a person in
an attempt to enhance a specific physical characteristic; for example, adding genes for growth
in an attempt to produce a tall individual. ELIAS & ANNAS, supra note 32, at 267.
59. Eugenic genetic engineering is the attempt to alter or improve complex human traits
that are at least partially genetic in origin, i.e., intelligence, athletic ability, or personality.
ELIAS & ANNAS, supra note 32, at 267.
60. Maxine F. Singer, Genetics and the Law: A Scientist's iview, 3 YALE L. & POL'"
REV. 315, 318 (1985).
61. J. Robert Nelson, The Human Problem of Human Genetic Engineering, in GENET-
ICS AND THE LAW 1I1 82 (1985).
62. Jean Porter, What Is Morally Distinctive About Genetic Engineering, I HUM. GENE
THERAPY 419, 420 (1990).
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theorists, who feel that the genetic code is what makes us human
and that any attempt to alter the code would begin a process that
could make us less human.63 In either instance, the basis for judging
the advisability of genetic engineering is a predetermined set of
moral principles or rules of conduct. Ethical decisions that are based
on pre-existing moral principles are termed a priori.64 Under a sys-
tem of a priori ethics, those things that are wrong have always been
and are always wrong. No matter what the situation, the "inherent
wrongness was believed by faith and by metaphysical opinion to be a
matter of 'natural' moral law or divine revelation."6 Thus, to inter-
fere with the human genetic code, even if the interference was for a
legitimate purpose, would violate an a priori scheme of ethics and
would be held to be against natural moral law.
The moral certainty with which one may act under an a priori
ethical system holds definite appeal. After all, who would not say
that they stood for the sanctity of the very thing that makes us
human. Yet to dismiss genetic engineering as unnatural without con-
sidering the potential benefits of the process seems harsh. This is
especially true when we consider that:
At various times, equality of rights, slavery, the subordination of
women, vegetarianism, and animal husbandry have all been de-
fended as natural; homosexuality, the accrual of interest on a
sum of money, intensive agriculture, the use of cosmetics and
the use of anesthetics in childbirth have all been condemned as
unnatural.66
In each case, opinions of what is morally natural have changed as a
result of a case-by-case analysis of the merits of each action. In ad-
dition, both philosophers and scientists agree that it is incorrect to
define humanness solely on the properties of DNA.67 The genetic
code is necessary to human existence, but factors such as society and
culture also play an important role in defining what is considered to
be human. Therefore, "[s]ince societies and cultures change, as well
as differ from each other, certain elements in the concept of human-
ness are variable, and there is no generally agreed upon definition of
63. Carol A. Tauer, Does Human Gene Therapy Raise New Ethical Questions?, I HUM
GENE TiERAPY 411 (1990).
64. Joseph Fletcher, Ethical Aspects of Genetic Controls: Designed Changes in Man,
285 NEw ENG. J. MED. 777 (1971).
65. Id. at 778.
66. Porter, supra note 62, at 420.
67. Singer, supra note 60, at 325-28; see also Fletcher, supra note 64, at 781.
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what 'humanness' requires. '"68 The a priori argument against human
genetic engineering must fail because, while the genetic code is wor-
thy of awe and respect, it is not the thing that defines the natural
moral law of being human. Whether human actions are natural "in a
normative sense, is defined by what is characteristic of human life as
a whole, namely, our capacities for intelligent self-direction, and not
by the biological processes that sustain our life, but do not give it its
characteristic shape. '" 9
How, then, should we determine whether the advance of genetic
manipulation in humans is ethical if we do not use the a priori sys-
tem? Once again, we are faced by the difficult task of attempting to
define what is human. The task is made even more difficult when we
discover that some who have considered the problem have concluded,
"[Tjhe fact is that most of our discourse about the ethics of biomedi-
cal innovation is a semantic swamp, because what we mean by
'human' and ergo by 'humanistic' usually remains vague and poorly
defined."
70
The most logical way out of the swamp appears to be that pro-
vided by the school of "virtue ethics."71 Under this approach, the
agent and the action are seen as one and analyzed according to their
effect on humans and human society.72 Thus, the key question to be
asked in determining if conduct is ethical is not whether we have a
right to act, but, rather, what we become if we act. 73 Therefore, un-
like a priori ethics, consequences are factored into the ethical equa-
tion, and the merits of each case determine whether an action is
ethical.
Both religious and secular groups are able to agree on the basic
concept of the sanctity of human life. Listed among the fundamental
elements required by this concept are "a basic respect for human
beings, for their civil rights, their personal rights to the care and
defense of their bodies and minds, and their proxy rights for depen-
68. Tauer, supra note 63, at 413.
69. Porter, supra note 62, at 422.
70. Fletcher, supra note 64, at 781. Fletcher goes on to suggest that it is far past the
time when a definition acceptable to medical, ethical, and legal communities should have been
established, and he urges swift action to find a non-doctrinal sclution to this problem as
quickly as possible. Regrettably, since the time that this article was published in 1971, there
has been little progress toward any working definition of what it is to be human.
71. Keenan, supra note 25, at 289.
72. Keenan, supra note 25, at 289.
73. Keenan phrases the question in a slightly different way, but with the same result.
First, he says we must ask who are we, then who we should become and, finally, how we get
there. If an action does not move us toward the type of beings that we should become, it is not
ethical. Kennan, supra note 25, at 289.
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dent relatives who are either small children or incompetent."74 These
fundamental rights75 - the sanctity of life - form the basis for
both medical ethics in general and, more specifically, the ethics of
genetic manipulation. Thus, human beings are seen as subjects pos-
sessing the rights that are fundamental to the concept of the sanctity
of life. When we consider any act and the consequences of that act,
we must determine to what extent the act diminishes the sanctity of
life or, put another way, how much an act transforms a human. into
an object.76 Thus, we see an act as morally wrong when it objectifies
a human being, and, "[i]n fact, the enduring critique of medical
work has been whenever the person is not treated as a person but as
a body or an object."
77
Presented with the virtue ethics question of what we become if
we act, we must then stay clear of actions that make human beings
objects and pursue the courses that give greater meaning to the sanc-
tity of life. In the context of modern medicine, where developing new
therapies is a trial-and-error process, the overriding concern of the
physician is to do no harm to the patient 78 and, in areas that are
untried, to proceed with caution. 79 In this light, we can clearly see
that "[t]he ethical grounds from which the argument for human
gene therapy arises are imperatives to relieve human suffering, pre-
vent premature death, and remove life-long burdens among the heav-
iest that persons must bear." 80 At this point we must begin to distin-
guish among the four categories of genetic manipulation (somatic
cell therapy, germ-line therapy, enhancement genetic engineering,
and eugenic genetic engineering), because the potential for dehu-
74. Nelson, supra note 61, at 83.
75. Dr. Fletcher takes issue with the use of the term "rights" to describe the controlling
factor in the test for ethical behavior. He prefers to think of human needs as the factor on
which the test hinges. Under Fletcher's approach, "[r]ights are nothing but a formal recogni-
tion by society of certain human needs, and as needs change with the changing conditions of
society so rights should change too." Despite the difference in terminology, the thrust of
Fletcher's test for the ethical acceptability of a medical process using genetics is also the re-
duction of human suffering. Fletcher, supra note 64, at 782.
76. Any act that treats a human being as an object has always been perceived as im-
moral because such acts are generally acts of oppression. Slavery is a classic example of an act
of oppression that creates objects of human beings. Keenan, supra note 25, at 293.
77. Keenan, supra note 25, at 292.
78. Dr. W. French Anderson endorses this approach in an editorial he wrote prior to the
first human trials using somatic cell gene therapy. W. French Anderson, What's the Rush?, I
HUM. GENE THERAPY 109 (1990). This sentiment is also embodied in the moral motto of
medicine: Primum non nocere - first of all, do no harm. Nelson, supra note 61, at 83-84.
79. Nelson,.supra note 61, at 83-84.
80. John C. Fletcher, Controversies in Research Ethics Affecting the Future of Human
Gene Therapy, I HUM. GENE THERAPY 307 (1990).
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manization increases with each step.81
The first level of genetic manipulation is somatic cell gene ther-
apy, which as we have discussed, involves the alteration of body cells
in the attempt to cure an existing genetic defect. This type of gene
therapy affects only the recipient of the genetically altered material
and cannot be passed on to future generations .&I Thus, on the sur-
face there seems to be only one major difference between somatic
cell gene therapy and conventional medicine: Conventional medicine
attacks the source of the disease. For those who favor an a priori
ethical system, this presents considerable problems. We must re-
member, however, that "DNA within cells is not inviolate; for exam-
ple, within the DNA of many organisms is found DNA from sepa-
rate entities, viruses, which inserted itself either generations ago or
during a recent infection."83 In addition, the structure of DNA is not
fixed; rather, it changes through natural mutation or by shuffling,
repeating and/or deleting pieces. Throughout the "[a]ddition or sub-
traction of a single segment of DNA, whether as a result of an en-
tirely natural process or as a result of genetic engineering, does not
make a significant difference to the identity of the organism." '84
Applying the ethical framework that we have developed, the
process of somatic cell gene therapy is no more: objectionable than
the use of modern medicine, for both seek to relieve human suffer-
ing.85 Therefore, when physicians employ somatic cell gene therapy
to combat diseases such as ADA or melanoma, we become a species
that is more concerned with the sanctity and preservation of life.
The ethical propriety of gene therapy becomes somewhat more
complex when we move from the consideration of somatic cell ther-
apy to the use of germ-line gene therapy. Germ.-line therapy is con-
ducted in the germ cells or gametes, the cells that are designed for
reproduction of the species.8 6 Genetic alterations in these cells would
prevent a defect from being inherited by future generations and thus
would affect the content of the human genetic pool.87 There has been
no attempt to use germ-line therapy in humans to date, but experi-
81. Keenan, supra note 25, at 289.
82. SPLICING LIFE, supra note 31, at 11-20.
83. Singer, supra note 60, at 328.
84. Singer, supra note 60, at 325.
85. Generally speaking, the view of the scientific communit:y is that somatic cell gene
therapy does not differ substantially from organ transplants or bone marrow injections. Judith
Areen and Patricia King, Legal Regulation of Human Gene Thercpy, I HUM. GENE THERAPY
151 (1990).
86. Singer, supra note 60, at 329.
87. Singer, supra note 60, at 329.
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ments in animals have shown that the transmission of altered genetic
material from one generation to another is possible even though the
success rate has been low.
88
Two techniques currently being used on laboratory animals
could be used to alter human germ cells. First, given that the human
male produces sperm cells continuously from puberty until death, the
alteration of the cells could take place in the adult male. This ap-
proach may not be feasible because it is very difficult to target the
specific cells to be altered.8 9 The second possible method of altering
germ cells is to genetically modify embryonic cells before they begin
to differentiate. 90 If this were done, all the cells of the developing
fetus, including the germ cells, would be affected by the modifica-
tion.91 This method of "germ-line genetic modification is more ad-
vanced scientifically, . . . [however,] it is ethically and politically
more controversial because it requires the manipulation of early
human embryos." 92 Thus, germ-line gene therapy presents us with
several levels of ethical problems: Is the alteration of future genera-
tions who cannot speak for themselves ethical and, if so, how should
the genetic alteration take place?
One of the first concerns of those who question the advisability
of germ-line therapy is the effect of the therapy on the human ge-
netic pool. In the long run, the argument goes, the elimination of
what we believe to be harmful genes from the human gene pool will
reduce the species' ability to adapt to changing environmental condi-
tions and thus reduce the chance of overall survival. Put another
way, the proponents of this theory would answer the question of
"what would we become if we conduct germ-line gene therapy" by
saying that we would become less likely to survive as a species.
Under the virtue ethics system, any action that would reduce the
chance of survival of the species would quite probably be seen as
unethical. However, this objection to germ-line therapy fails to con-
sider two important factors. First, the fact that the gene has been
removed by genetic manipulation does not mean that it could not be
reintroduced by the same process if it were discovered that the gene
served a beneficial purpose.
If we could engineer away the 'defects,' we could presumably
engineer them back were we to discover that they had a desira-
88. Tauer, supra note 63, at 413.
89. Tauer, supra note 63, at 415.
90. Tauer, supra note 63, at 415.
91. SPLICING LIFE, supra note 31, at 11-20-21; see also Tauer, supra note 63, at 415.
92. Tauer, supra note 63, at 415.
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ble side effect (unless one generation were to take the unlikely
step of engineering into the next generation an aversion to ge-
netic engineering or the inability to engage in it). 93
Second, while there is no doubt that certain genes will be eliminated
from the gene pool, there is no assurance that other genes will not be
introduced. Therefore, rather than being restricted, the human gene
pool may be expanded, and human beings will become more, as op-
posed to less, adaptable to ecological changes.
In addition, this ecological argument against germ-line therapy
seems to assume that the natural production of genes is the key to
evolution. This, however, is not the case. Nature does not plan evolu-
tion by the production of genes; rather, evolution occurs by random
choice through the process of natural selection. 4 Human interven-
tion in the selection process merely imposes a plan on the system and
to some "[i]t makes more sense to plan for the future event with
imperfect information, than to sit idly by waiting for the genetic rou-
lette wheel to stop spinning."95
In this light, what initially appeared to fail the virtue ethics test
for ethical action now seems to be in the best interest of society.
Through the practice of germ-line therapy, we would become more
concerned with both the life of those affected by the genetic disorder
and the life of the species. Even so, there is a long-standing ethical
aversion to performing medical procedures on persons without their
consent. The future generations who will be affected by germ-line
therapy are not in a position to consent to treatment, but their par-
ents may legally consent for them. In addition, we may test the eth-
ics of an action by placing ourselves in the position of the future
generations. If we were able to conduct germ-line gene therapy but
did not, the future generations affected by the genetic disease would
be harmed.96 This, of course, would violate the medical principle
that no harm should result from the practice of medicine. Thus, even
without consent, the application of germ-line gene therapy satisfies
the virtue ethics test for ethical action.
E. Joshua Rosenkrantz, a former law clerk to Justice William
93. E. Joshua Rosenkrantz, Custom Kids and the Moral Duty to Genetically Engineer
Our Children, 2 HIGH TECH. L.J. 1, 23 (1987).
94. Id. at 24.
95. Id. In addition, the author points out that another problem presented by this argu-
ment is that human beings have .already altered the gene pool through the use of modern
medicine. Thus, the internal human manipulation of germ cells may only be a balance to what
has come before. Id.
96. Fletcher, supra note 28, at 542-43.
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Brennan, 97 places a different emphasis on the use of genetic manipu-
lation when the process is to be applied to children and future gener-
ations. In this context, he argues that a parent has a moral duty to
genetically rescue a child from the suffering of a genetic disease.
9 8
This duty derives from the fact that, "If a prenatal diagnosis shows
that a fetus has a serious single-cell defect and the mother opposes
abortion, prenatal treatment may be essential to prevent the damage
that will occur when a gene necessary for normal development is
missing. ''" Thus, the duty would apply to both germ-line and so-
matic cell therapy.
Under Rosenkrantz's theory, a rescue is defined as an act that is
beneficial to the rescued and that does not change the identity of the
person who is rescued.100 In the case of genetic engineering, it is
clear that the alleviation of suffering caused by genetic disease would
certainly be beneficial to a person afflicted with such a disease. In
addition, the identity of an individual, like the definition of what is
human, is not dependent on genes alone. Yet, even if genetics were
the sole determiner of an individual's identity, "[m]ost people do not
understand that in most cases manipulation of DNA results in only a
very small change in the genetic make-up of an organism."101 Thus,
from a strictly scientific point of view, the individual's identity is not
changed by genetic manipulation. Rosenkrantz answers the identity
question in a slightly more humanistic fashion by applying a rule of
"closest continuation."'0 2 Under this theory, if the person being res-
cued is causally dependent on the person doing the rescuing and the
rescued person is in the closest relationship to the person rescuing
him, then the identity of the person before and after the rescue is the
same. Put in a simpler fashion, "[o]ur identity analysis boils down to
no more than a comparison of the person that the egg would have
produced (but for the intervention) to the person that it will produce
(after the intervention)." 1 °3
When this test is applied to either possible technique for germ-
line gene therapy, we see that both prongs are satisfied. The post-
97. Mr. Rosenkrantz was clerk to Justice Brennan during the 1987-88 term of the Su-
preme Court.
98. Rosenkrantz, supra note 93.
99. John A. Robertson, Genetic Alteration of Embryos: The Ethical Issues, in GENET-
ICS AND THE LAW Iil 118 (1985).
100. Rosenkrantz, supra note 93, at 25-27, 38.
101. Singer, supra note 60, at 325.
102. Rosenkrantz, supra note 93, at 27-28. The closest continuation theory applied by
the author is the work of the philosopher Robert Nozick.
103. Rosenkrantz, supra note 93, at 41.
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genetic manipulation child is: (1) causally dependent on; and (2) in
the closest relationship to the pre-gene therapy sperm cell or embryo
- the only real difference between the two being the absence of the
genetic defect. Therefore, according to Rosenkrantz, not only is it
ethical to conduct germ-line gene therapy, but it is also the duty of a
parent to use gene therapy to rescue a child from the suffering
caused by genetic disease.104
Of course, there must be limits to the moral duty of a parent to
perform a genetic rescue. The easiest and most understandable limit
on such a duty would parallel the limits on a parent's moral duty to
aid a child in other ways. The most obvious parallel to the genetic
rescue is the duty to provide conventional medical care when a child
is ill. Using this principle as a guideline, Rosenkrantz creates a "par-
allel cure" theory, under which "parents must rescue their child ge-
netically (all else being equal) to the extent that they would be mor-
ally bound to cure or compensate for a child's trait conventionally,
once it manifests itself."1 5
Now that we have established that the overall concept of germ-
line therapy is ethical under the virtue ethics system, we must move
to the second level of ethical questions and determine if it is ethical
to pursue germ-line gene therapy using either of the techniques cur-
rently being investigated. There seems to be very few ethical
problems with the technique of altering the cells that produce sperm
in the adult male because an adult could consent to the process. As
we have discussed, however, this process is the more problematic of
the two techniques. Therefore, we must turn our attention to the eth-
ical considerations of genetic manipulation in the pre-differentiated
human embryo.
To begin with, the possibility of human germ-line therapy is, at
present, many years away.106 Yet the steps leading to human trials
with germ-line therapy require considerable ethical analysis because
much of the research involved will require the use of human em-
bryos. 10 7 It is important to note that "[iun contrast to an ethos of
deep approval for somatic cell therapy, the moral climate surround-
ing . . . [research on in utero and ex utero human fetuses, and re-
104. Rosenkrantz, supra note 93, at 38-44.
105. Rosenkrantz, supra note 93, at 46.
106. Writing in 1983, Fletcher placed the potential date for the use of germ-line therapy
at 50 to 100 years in the future or well after somatic cell therapy has become highly success-
ful. Fletcher, supra note 28, at 534. Even if Dr. Fletcher's prediction should be revised in the
wake of the first human trials with somatic cell therapy, the adver,t of human use of germ-line
therapy is still in the distant future.
107. Fletcher, supra note 80, at 307, 311-21; see also Tauer, supra note 63, at 415-16.
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search using in vitro fertilization] is in a stage of polarization and
paralysis of action, especially in the federal sector of U.S.
science." 108
The federal government is not the only area in which these top-
ics elicit a polarized response. Religious groups, particularly the Ro-
man Catholic church, have condemned the practices of in vitro fertil-
ization and fetal experimentation." 9 In short, the religious argument
against in vitro fertilization is that it removes the unity of husband
and wife from procreation and dehumanizes procreation and
parenthood.110 The Church's opposition to fetal research is also well
known. In short, the Church's opinion is based on the belief that life
begins at conception and that any harm or destruction to early
human embryos is an immoral act."'
From a logical point of view, the position of the Catholic
Church on this issue is undermined to some degree by the Church's
inconsistent stand on the human application of gene therapy." ' 2 The
Vatican has approved the use of somatic cell gene therapy after birth
in cases of persons suffering from serious diseases. 1 Yet, the
Church steadfastly refuses to endorse the use of such therapy prior
to birth. However, this position appears to contrast the Catholic be-
lief that the fetus is just as much a person before and after birth.1""
The Catholic Church appears to be caught in the awkward position
of saying that fetuses are entitled to all the rights of an adult (in-
cluding the ability to use somatic cell gene therapy), 1 5 but that any
adult who tries to develop direct medical care for the fetus (a process
that must involve human research to determine safety and efficacy),
in the hope of reducing the suffering after birth, is committing an
108. Fletcher, supra note 80, at 309.
109. Richard A, McCormick, How BRAVE A NEW WORLD? 303, 312-17 (1981); see
also LeRoy Walters, Ethical Issues in Human In Vitro Fertilization and Embryo Transfers,
in GENETICS AND THE LAW 111 215 (1985).
110. For a more in-depth discussion of the religious objections to genetic alteration and
in vitro fertilization, see Paul Ramsey, Fabricated Man: The Ethics Of Genetic Control
(1977).
111. Keenan, supra note 25, at 295. For a general discussion of various religious atti-
tudes in this topic, see McCormick, supra note 109, at 281-335.
112. Some Catholic philosophers have argued that the traditional Catholic values do not
support a certain and complete moral objection to any conduct affecting early human embryos.
In addition, the Church's own official statements, on occasion, have noted that there is disa-
greement over the moral questions concerning early human embryos. Tauer, supra note 63, at
416.
113. Rosenkrantz, supra note 93, at 35 n.142.
114. Rosenkrantz, supra note 93, at 35-36.
115. Somatic cell therapy in a fetus essentially results in germ-line therapy since, at the
time of the manipulation, the fetus is undifferentiated. When the fetus' cells begin to differen-
tiate, the cells will all carry the newly inserted genes. Tauer, supra note 63, at 416.
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immoral act.
This is a perfect example of why the a priori ethical approach is
ill-suited for the analysis of scientific developments. Therefore, we
shall apply the virtue ethics analysis to in vitro fertilization and the
research necessary for the development of germ-line gene therapy.
What, then, do we become if we carry out the process of in vitro
fertilization and fetal research? Once again, we must look at the
characteristics that make us human. We begin the analysis by notic-
ing that "[m]an is a maker and a selector and a designer, and the
more rationally contrived and deliberate anything is, the more
human it is."' 18 Thus, it seems that in vitro fertilization is a very
human process because it is rational and carefully planned. In addi-
tion, the ability to reduce suffering and eliminate genetic disorders
through the use of genetic manipulation and in vitro fertilization cre-
ates a possible benefit to all human beings. Surely we cannot believe
that it is debasing our humanness to accomplish, through rational
planning, a world with less human suffering. On the contrary, it
seems that "human life would be debased if we could easily do some-
thing fundamentally to improve that life but refrained from doing
so.""' 7 Therefore, it appears that using in vitro fertilization to de-
velop the process of germ-line gene therapy makes us more, and not
less, human.
There is, however, one gnawing ethical problem hidden in the
otherwise bright picture just painted: the ethical considerations of
fetal research. These considerations boil down to the question of
when, if ever, is it proper to develop human embryos for in vitro
research. The answers to this question, as one might expect, are va-
ried. In Great Britain, research is allowed on human fetuses for up
to fourteen days after fertilization;" 8 however, in West Germany,
the Bundestag condemned all genetic research on embryos and rec-
ommended that it be a federal criminal offense to attempt to bring to
term an embryo that had been genetically manipulated. ' The
United States has taken a different approach to the problem. In
1975 a moratorium on research using in vitro fertilization was de-
clared, and the Department of Health and Human Services (DHHS)
appointed an Ethical Advisory Board (EAB) to study the matter.
116. Fletcher, supra note 64, at 780.
117. Rosenkrantz, supra note 93, at 35.
118. The House of Commons voted on the matter on April 23, 1990, and by a vote of
364-193 approved the use of fetal research. Tauer, supra note 63, at 415.
119. Tauer, supra note 63, at 415.
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The EAB approved the limited use of embryo research,12 but
DHHS never implemented the proposal.121 Thus, the moratorium on
federal funding for in vitro embryo research continues to be in ef-
fect.122 In vitro embryo research may be conducted by using private
funds if not prohibited by state law; however, some commentators
feel that the federal research ban discourages and inhibits private
research.121
In vitro research on the human embryo, or, more precisely, the
pre-embryo, is important to the development of human gene therapy
because, before germ-line gene therapy can begin, scientists must
study the development of the human zygote"2 4 to determine how ge-
netic diseases begin and function. In addition, researchers must de-
termine whether the process of germ-line therapy actually does pre-
vent the inheritance of genetic diseases in humans. Therefore, if the
potential benefits of human germ-line gene therapy are to be realized
in the United States, we must as a society determine whether it is
ethical to use human pre-embryos in research. The present paralysis
or procrastination being practiced by the federal government is
clearly unacceptable. This is not meant to belittle the government,
for this is a truly difficult question, but other governments have
120. The EAB laid out six criteria that would have to be met if research using human
zygotes was to be ethical: 1) research must comply with existing guidelines for human experi-
mentation; 2) research must be designed primarily to establish the safety and efficacy of trans-
ferring genes to the zygote, thus focusing on the life of the zygote; 3) the scientific merit of the
study must be exceptional and the results obtainable only through the use of human embryos;
4) germ cells should be obtained only from informed and voluntary donors; 5) no embryo
should be allowed to develop past 14 days after fertilization - the normal time for implanta-
tion; and 6) researchers should promptly report any greater than normal risk of abnormalities
from the use of the process. Fletcher, supra note 28, at 535-36.
121. Tauer, supra note 63, at 416. The EAB was allowed to lapse in 1979, and DHHS
has not attempted to restore the EAB. Fletcher, supra note 64, at 309.
122. The 1975 moratorium affects all research involving in vitro fertilization and is dif-
ferent from a moratorium imposed by the NIH in 1989 on fetal tissue transplantation re-
search. In addition, federal funds are available for fetal tissue research when the product of
the research is not transplanted into a patient. Fletcher, supra note 80, at 311-16.
On July 25, 1991, the United States House of Representatives voted 274 to 144 to over-
turn the ban on fetal tissue research. The bill voted on by the House would cover areas that
are addressed by both the 1975 and 1989 moratoriums. Despite the House vote, it was widely
expected that President Bush would veto the bill. Gwen Ifill, House Approves Fetal Tissue
Use in Federally Financed Research, N.Y. TIMES, July 26, 1991, at Al l. A similar bill was
approved by the Senate Labor and Human Resources Committee on February 6, 1992. David
Brown and Guy Gugliotta, On Capitol Hill-Fetal Tissue Research Backed, WASH. POST,
Feb. 6, 1992, at All.
123. Fletcher, supra note 80, at 310.
124. A zygote is the cell that results from the union of a male and a female gamete until
it begins to divide. DORLAND'S ILLUSTRATED MEDICAL DICTIONARY (26th ed. 1981). The de-
veloping life technically is a pre-embryo between the first cell division and the second week of
development, at which time it becomes an embryo.
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reached a decision on the matter and so, too, must ours. 125
Once again, we must begin our ethical analysis by looking at
the merits of the case and the consequences of our actions and an-
swering the question of what we become if we proceed with fetal
research. If in vitro embryo research is used to advance gene therapy
techniques, as with somatic cell gene therapy, the ultimate merits of
the case are quite strong. If the technique can be perfected, human
suffering can be reduced. Thus, the ends for which the initial experi-
mentation are being conducted will lead us to something that is de-
sirable. This, however, is not the end of the inquiry because, to
achieve these ends, scientists must fertilize human eggs in vitro for
the sole purpose of using these zygotes for experiments.
If the products of these experiments were then implanted in a
womb and brought to term, the resulting children might suffer as
much or more than if they were born with the genetic defect that the
experiment seeks to cure. Therefore, conducting these experiments
would create suffering, which is clearly not a desired end. With this
in mind, it appears that the dividing line between ethical experimen-
tation and unethical experimentation should be drawn at the implan-
tation of the zygote into the uterus. This approach is similar to the
one taken by the EAB and Great Britain, both of which allow re-
search on an embryo up to fourteen days after fertilization if good
cause is established.12
In allowing research on zygotes only up to the point at which
they may begin to develop sentience, 127 and following the other crite-
ria laid out by the EAB, we are able to show respect for the moral
status of the zygote while at the same time, we distinguish the moral
standing of the zygote from that of the fetus.'2 8 Yet, even if the
moral standing of the zygote is protected, there still remains the
problem that research of this nature treats the zygote - a potential
125, It could be argued that the federal government has made a decision by its failure to
act, but this would be a decision by default. What is needed to resolve this difficult problem is
a decision based on an active assessment of the situation.
126. Robertson, supra, note 99, at 119. The 14 day period is established because, at or
about 14 days after fertilization, the nervous system begins to differentiate and the possibility
of sentience arises. Robertson, supra note 99, at 119.
127. As mentioned in note 126, 14 days after fertilization the nervous system begins to
differentiate and sentience starts to develop. Robertson, supra note 99, at 119. This is the point
by which implantation normally must be completed. Thus, it is also the point at which experi-
mentation must stop. Fletcher, supra note 28, at 536.
128. The zygote is unable to fully develop without the positive step of implantation. At
the point the zygote is implanted in a womb, it becomes a potential fetus. Fletcher, supra note
28, at 536. Dorland's Medical Dictionary defines a fetus as unborn offspring in the period of
post embryonic development. Embryonic development is the period from two to eight weeks
after fertilization. DORLAND'S MEDICAL DICTIONARY 493 (26th ed. 1981).
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human - as an object. Unlike other acts that make human beings
objects, however, here we are dealing with an act that is not
designed to be oppressive. Thus, research that treats human zygotes
as objects may still be ethical if it is conducted to reduce human
suffering rather than conducted for oppressive purposes. We must be
alert, however, for if this type of research was used for oppressive
ends, the result would be far more devastating than any previous act
that treated human beings as objects. 12 9
In light of this observation, it is clear that the enhancement of
specific traits and the eugenic improvement of the species are appli-
cations of genetic manipulation that, at present, are not ethical be-
cause they are based on the concept that some human beings are
more valuable than others. This sort of value determination results in
the treatment of human beings as objects for an immoral purpose,
and, unlike the previous forms of oppression, those oppressed by
eugenics would not have the opportunity to resist.13 0 Therefore, if we
as a species were to practice enhancement or eugenic genetic manip-
ulation, we would become oppressors to all those people who did not
possess those traits on which we placed greater value.
The position that genetic manipulation for enhancement or
eugenics is not ethically advisable is backed, to some degree, by pop-
ular opinion. A public opinion poll taken by Louis Harris under the
auspices of the Office of Technology Assessment in 1986 showed that
53 % of the 1,273 adults who responded were against the use of ge-
netic manipulation for enhancement.1 31 On the other hand, 62% of
those surveyed approved of the use of germ-line gene therapy to cure
fatal genetic diseases." 2 Thus, both ethical considerations and, to a
lesser degree, popular perception favor the use of gene therapy for
the purpose of combating diseases and object to its application for
enhancement or eugenic purposes.
IV. The Need for Regulation
Some authors, Professor Sheldon Krimsky 33 in particular, point
out that an ethical boundary for genetic manipulation based on the
129. Keenan, supra note 25, at 293.
130. Keenan, supra note 25, at 293.
131. Sheldon Krimsky, Human Gene Therapy: Must We Know Where to Stop Before
We Begin?, I HUM. GENE THERAPY 171 (1990). Other results from this poll indicate that only
18% of those surveyed strongly approved of improving intelligence levels through the use of
genetic manipulation and only 16% favored the improvement of athletic ability. Fletcher,
supra note 80, at 308.
132. Krimsky, supra note 131, at 173.
133. Department of Urban and Environmental Policy, Tufts University, Boston, MA.
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distinction between curing disease and enhancing traits rests on neb-
ulous scientific grounds because the definition of disease is in a con-
stant state of flux. Yet, this may be precisely why an ethical princi-
ple for genetic engineering should be based on such a distinction: It
is able to change with the perceptions and needs of society. Science
can be seen in any of three ways or a combination of the three. First,
science may be seen as the search for truth in the natural world.
Second, it may be seen as a particular method of inquiry - the
scientific method. Third, it may be seen as a human enterprise dedi-
cated to the betterment of human beings.13' There can be no doubt
that "[s]cience is now a public and social enterprise not only because
much of its financial support comes from the public but just as im-
portantly because the implications and impact of science are public
and social."'35 This is especially true for genetic: engineering. There-
fore, it is argued that because of the public and social implications
and impact of science, particularly genetic manipulation, government
regulation of science is necessary.
Many scientists, however, feel that the best science is that
which is conducted without social constraint. To this end "[m]any
scientists claim .. . [that] they have a right of free inquiry - a
right to research - that governmental constraints on scientists'
choice of research topics and methods violates."' 36 Thus, the idea
that science is an enterprise devoted to the betterment of human be-
ings creates a tension between the good of society and the freedom to
research.13 7 There must, of course, be limits imposed on any freedom
when the exercise of that freedom will harm the health, safety, and
welfare of others. Therefore, the state may regulate research because
society may be harmed by either the research process itself or the
product of the research.' 3 8 In addition, it must be realized that the
interests of the public and the interests of scientists will not always
be the same. Therefore, we must concede that "[s]cientists cannot
134. Daniel Callahan, Ethical Issues in the Control of Science, in GENETICS AND THE
LAW If 19 (1980).
135. Id. at 21.
136. John A. Robertson, The Scientist's Right to Research and the Legitimacy of Gov-
ernmental Regulations, in GENETICS AND THE LAW il 29 (1980). Many times this argument is
phrased in the context of the First Amendment as part of a growing movement to recognize a
right to gather information. If such a constitutional right to research exists, then government
could only regulate scientific research by establishing a compelling state interest. Id. at 29-30.
137. Callahan, supra note 134, at 20.
138. Robertson, supra note 136, at 30. In either case, the government is regulating the
process by which the research is conducted, in one case by saying how it is to be carried out
and in the other by saying that it cannot be carried out because of the harm produced by the
end-product. In terms of the First Amendment, these types of regulations fall under the head-
ing of time, place and manner restrictions. Robertson, supra note 136, at 32.
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fully regulate themselves in the public interest because they are not
necessarily representative of the public."1 9 Despite the initial suc-
cess of self-regulation by scientists in the field of genetic engineer-
ing,14 the need for outside regulation is apparent due to the severe
consequences that could arise if the process was abused.
Even with a system of governmental regulation, some scientists
will attempt to avoid the established protocol and conduct research
as they please. This is clearly shown by the incident in 1980 involv-
ing UCLA researcher Martin Cline. Dr. Cline "will go down in
medical history as the first person to attempt to transplant cloned
genes into human patients, his particular purpose being to effect a
cure for the dreaded globin disease beta thalassemia. '"14 Dr. Cline
performed the experiments in Italy and Israel, but failed to receive
approval from either government or from the necessary review
boards at UCLA. " "
When the violations were reported, the National Institute of
Health (NIH) conducted a review of the matter. The NIH con-
cluded that Dr. Cline was in violation of the established procedure
and removed federal funding from Dr. Cline's projects. " ' In a more
139. Callahan, supra note 134, at 24. The position that scientists should not be allowed
to regulate themselves has been advanced by many prominent members of the legal commu-
nity, including Judge David Bazelon of the District of Columbia Court of Appeals and Senator
Albert Gore. David Bazelon, Coping With Technology Through the Legal Process, 62 CoR-
NELL L. REV. 817 (1977); Senator Albert Gore and Steve Owens, The Challenge of Biotech-
nology, 3 YALE L. & POL'Y REV. 336 (1985); Senator Albert Gore, A Congressional Perspec-
tive, in BIOTECHNOLOGY IMPLICATIONS FOR PUBLIC POLICY, THE BROOKINGS INSTITUTE
(1985).
140. In 1974, the National Academy of Science (NAS) called together a group of con-
cerned scientists to discuss the potential hazards presented by genetic engineering experiments.
The committee proposed a worldwide moratorium on certain high-risk experiments and called
on the NIH to create an advisory body to oversee the development of rDNA processes. In
addition, the committee called for an international conference on rDNA. The conference was
held at the Asilomar Conference Center in Palo Alto, California in February 1975 and was
attended by representatives of 150 countries. During the seven months between the NAS com-
mittee's proposal and the conference, the international moratorium was observed; however,
many commentators believe that this was due in great part to the list of distinguished scientists
who agreed to support the moratorium. Judith P. Swazey et al., Risk and Benefit, Rights and
Responsibilities: A History of the Recombinant DNA Controversy, 51 S. CAL. L. REV. 1019
(1978).
141. Ira H. Carmen, CLONING AND THE CONSTITUTION: AN INQUIRY INTO GOVERN-
MENTAL POLICY MAKING AND GENETIC EXPERIMENTATION 93 (1985).
142. Id. Dr. Cline and his team claim that they were not trying to avoid regulatory
authorities in the United States by performing the experiments abroad; rather, they said they
chose to work in Italy and Israel because the incidence of beta thalassemia is higher there than
in the United States. Gina Kolata, Human Gene Treatment Stirs New Debate, SCIENCE, Oct.
24, 1980, at 407.
143. The total amount of the canceled grants was in excess of $190,000. The NIH also
placed stricter conditions on Dr. Cline when he applied for future grants. Marjorie Sun, Cline
Loses Two NIH Grants, SCIENCE, Dec. II, 1981, at 1220.
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recent incident, one of America's leading molecular biologists, Dr.
David Baltimore, has been implicated in the cover-up and use of fal-
sified data concerning the effect of transferred genes on the human
immune system. 14  Dr. Baltimore did not conduct the research in
question, but he was the co-author of the paper 'in which it appeared,
and he initially defended its contents. 145 Dr. Cline's failure to gain
proper approval for his studies and Dr. Baltimore's initial reaction to
the criticism of his paper are examples of incidents in which a scien-
tist has been too involved in his/her research to be able to view the
research objectively. Therefore, in order to benefit society, the appli-
cation of genetic manipulation should be monitored by a governmen-
tal board or agency composed of members from all aspects of human
life.
V. The Present Regulatory System
The present system of regulation for rDNA technology began in
1974 when the NIH established the Recombinant DNA Advisory
Committee (RAC). The RAC is composed of twenty-five members
drawn from the fields of law, molecular biology, medicine, ethics,
and the general public; its initial task was to develop procedural
standards for NIH-funded rDNA experiments. 14 These standards,
the Federal Guidelines for Research Involving Recombinant DNA
Molecules (NIH Guidelines), were published in 1976 14 and have
since been revised.1 48 The central focus of the NIH Guidelines is to
prevent environmental contamination by the rDNA-altered organism
used in the experiment. In general, the NIH Guidelines establish
levels of physical and biological containment necessary for the safe
handling of genetically altered organisms. 4 9 In cases where serious
risk is presented, scientists must submit detailed data, including tox-
icity studies, to the RAC on the host/vector system that they intend
to use. 150 The RAC makes its recommendation and then passes the
144. Philip J. Hilts, Crucial Research Data in Report Biologist Signed Are Held Fake,
N.Y. TIMES, Mar. 21, 1991, at Al.
145. Id.
146. Naumann, supra note 35, at 65.
147. 41 Fed. Reg. 27901-27943 (1976).
148. 51 Fed. Reg. 16958-16985 (1986).
149. Physical containment refers to the procedure necessary to ensure that no material
escapes the physical area in which experiments are conducted. The Guidelines establish four
levels (p-I through p-4) of physical containment. P-4 is the maximum control, requiring air-
tight experimentation areas accessed through glove ports. Biological containment, on the other
hand, refers to the ability of the genetically altered organism to survive outside the special
conditions maintained in the laboratory, Talbot, supra note 24, at 808-09.
150. Edward L. Korwek, The NIH Guidelines for Recombinant DNA Research and the
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application on to the director of NIH for final approval.1 51 Finally,
the NIH Guidelines require an institution conducting even low-risk
experiments to establish an Institutional Biosafety Committee (IBC)
to ensure that the procedures established in the NIH Guidelines are
followed.' 52
In 1984, the RAC realized that the initial guidelines had not
fully taken into account the possibility of human applications of ge-
netic manipulation. Therefore, it established the Human Gene Ther-
apy Subcommittee 153 to explore the specific problems of human gene
therapy. The Subcommittee proposed and the RAC approved a doc-
ument titled "Points to Consider in the Design and Submission of
Human Somatic-Cell Gene Therapy Protocols," which:
formally requests . . . [a researcher to provide] information on
a variety of topics that the Human Gene Therapy Subcommittee
considers relevant to the task of deciding whether to recommend
approval of a specific protocol for human gene therapy; implic-
itly, however, it imposes requirements on researchers seeking ap-
proval that go beyond the RAC Guidelines. 54
In addition, human subjects in rDNA research experiments are cov-
ered by the general federal regulations concerning the use of human
beings in all experiments.'55 Under these regulations, each research
facility is required to establish an Institutional Review Board (IRB)
to review protocols using human subjects.561 Approval for such re-
search is given only if the risk to the human participants is minimal
or in proportion to the potential benefit from the protocol . 57 The
human subjects or their legal representative must also give informed
Authority of FDA to Require Compliance with the Guidelines, 35 FOOD DRUG CosM LJ.
633, 636-38 (1980).
151. Id. at 638.
152. Id.
153. The subcommittee is composed of 15 members drawn from the RAC who serve
either one, two, or three year terms. The staggered term system allows the composition of the
subcommittee to rotate and thus not be overly influenced by any one group. Areen and King,
supra note 85, at 151 n.5.
On February 10, 1992, the RAC voted unanimously to merge the subcommittee into the
RAC. All gene therapy protocols will now be reviewed by the combined group. The Blue
Sheet, FDC REPORTS, Feb. 19, 1992, at 7.
154. Areen and King, supra note 85, at 152. Examples of these additional considerations
are that: 1) researchers are asked to confirm that patients will agree to at least three to five
years of follow-up; 2) participants in the protocol be advised of the risks of withdrawing from
the study after receiving genetically altered material; 3) researchers agree to notify NIH if
any serious adverse effects occur; and 4) researchers agree to keep the identity of the patients
and their families confidential.
155. 45 C.F.R. §§ 46.101 et seq. (1988).
156. Areen and King, supra note 85, at 151-52.
157. 45 C.F.R. § 46.111 (a)(1), (2) (1988).
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consent to the process.' 58 Therefore, "[a]ny protocol for human gene
therapy conducted at an institution receiving NI[H research funds
will need the approval of at least four different regulatory bodies
before going forward: the local IBC, the local IRB, the RAC and the
FDA." 159
VI. Problems with the Present System
This impressive array of regulatory authority is deemed neces-
sary to protect the public at large and the individual research sub-
jects from any possible ethical or ecological harm resulting from the
use of gene therapy. Yet, in spite of all its internal checks and bal-
ances, the system has some serious problems. To begin with, the
NIH Guidelines apply only to institutions that receive funding from
the NIH.' 60 In addition, the legal basis for the NIH's power to re-
quire compliance with the NIH Guidelines even for NIH-funded in-
stitutions is somewhat unclear. There are two main theories concern-
ing NIH's power to enforce the Guidelines: 1) the NIH promulgated
the Guidelines in accordance with formal agency rule-making proce-
dures; therefore, the guidelines are to be treated as agency rules; and
2) the basis of the NIH's power is derived from the contract between
the researcher and the NIH.' 6 '
In recent years, the contract theory has been gaining support
based on a ruling by the District of Columbia Circuit Court of Ap-
peals in Foundation of Economic Trends v. Heckler. '2 In Heckler
the court indicated "that NIH approval of genetic engineering ex-
periments is an explicit condition . . . [that] must be satisfied before
a scientist can receive federal funds for recombinant DNA re-
search."' 3 Under this approach, as in contract law, the non-occur-
rence of a condition (compliance with the Guidelines) prevents the
promisor's (NIH's) duty (funding) from arising." 4 The situation is
further complicated by the fact that NIH has never officially stated
the legal authority on which the NIH Guidelines are based.' 5 The
basis for the NIH's power to enforce the Guidelines is important
because, without proper authority, the NIH Guidelines are open to
158. 45 C.F.R. §§ 46.111, 46.116 (1988).
159. Areen and King, supra note 85, at 155.
160. Areen and King, supra note 85, at 152.
161. Korweck, supra note 150, at 636.
162. 756 F.2d 143 (D.C. Cir. 1985).
163. Naumann, supra note 35, at 67-68.
164. Korwek, supra note 150, at 636.
165. Korwek, Recombinant DNA and the Law: Review of Some General Legal Consid-
erations, 15 GENE I (1981).
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constitutional challenge.
Another problem with the present regulatory system is that the
NIH is not the only government agency involved in the regulation of
genetic engineering. Other agencies with regulatory concerns relat-
ing to rDNA are the Food and Drug Administration (FDA), the
Environmental Protection Agency (EPA), the Department of Agri-
culture (USDA), the National Science Foundation (NSF), and the
Occupational Safety and Health Administration (OSHA). While
many of these agencies have incorporated the NIH Guidelines into
their individual regulatory schemes, the potential for conflicting deci-
sions is still present. The following analysis will concern only the in-
teraction between the FDA and the NIH in the regulation of gene
therapy.
Beginning in 1979, the FDA asserted that its regulatory powers
extended to all new drugs and methods of producing new drugs.""8
The FDA interpreted this to mean that even when a drug made by
conventional means had been approved for use, the same drug when
made by another company or by different means would be a "new
drug." Therefore, generic drugs or drugs produced by rDNA
processes were to be included under the FDA's pre-marketing review
process.117 The United States Supreme Court ultimately upheld the
FDA's extension of power.' 68 In addition, the FDA claims authority
to regulate human gene therapy through its power to regulate all
clinical pharmaceutical testing.1 69 This proposition presents two
problems for the scientific community and the public at large. First,
the FDA's enabling statute gives the agency power to regulate drugs
and products used in clinical testing when they move in interstate
commerce.1 70 Therefore, it is possible to question the FDA's author-
ity to regulate gene therapy if the rDNA product given to the pa-
tient has not moved in interstate commerce. Second, some commen-
tators question the FDA's ability to require compliance with the
NIH Guidelines.
Under the basic principles of administrative law, an agency can-
not promulgate substantive or interpretive regulations unless the reg-
166. Naumann, supra note 35, at 70.
167. Naumann, supra note 35, at 70.
168. United States v. Generix Drug Corp., 460 U.S. 453 (1983). In Generix, the Su-
preme Court was presented with a manufacturer that claimed its generic product was not
subject to FDA review because the active ingredient had already received FDA approval. The
Court held that the term "new drug" applied to both the active and non-active elements of a
drug.
169. Naumann, supra note 35, at 71.
170. Naumann, supra note 35, at 71.
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ulations advance some provision of the agency's enabling statute. If
FDA were to incorporate the NIH Guidelines, the commentators
suggest that the only logical way to do so would be under the Good
Manufacturing Practices regulations (GMP) of the Food, Drug and
Cosmetic Act.17" ' The GMP regulations carry the force of law and
cover a wide range of practices, including those conducted in labora-
tories as well as those conducted in packaging and labeling.' 72 The
problem with incorporating the NIH Guidelines into the GMP regu-
lations is that the objectives of the two systems are quite different.173
The GMP regulations are designed to carry out 'the overall goal of
the Food, Drug and Cosmetic Act - purity of food and drugs to
ensure the safety of the people who use them -- while the NIH
Guidelines were established to "specify practices for conducting ba-
sic research and have nothing to do with assuring the identity,
strength, quality and purity of the products of the technology.' 74
Therefore, it appears that FDA would be going outside its adminis-
trative mandate in attempting to require compliance with the NIH
Guidelines.
VII. Attempts to Amend the Present System
The different purposes of the NIH and the FDA highlight the
potential for conflict in regulating human gene therapy due to the
overlapping jurisdiction of the agencies involved. These jurisdictional
conflicts will also lead to inconsistent regulations being issued by the
different agencies. Therefore, it is clear that some method of resolv-
ing the present difficulties in regulating genetic engineering must be
found. The government took steps in this direction when the White
House Office of Science and Technology created the Biotechnology
and Science Coordinating Committee (BCSS) in 1985.17" The BCSS
was designed to provide all the agencies regulating genetic engineer-
ing with a forum in which they could discuss the scientific and regu-
latory problems created by the new technology. In this way, general
scientific understanding could be reached and all agencies would be
able to regulate even-handedly. The problem with the BCSS is that
it was given no power to resolve interagency disputes or to enforce its
recommendations. 176 Therefore, the BCSS lacks the authority to be
171. Korwek, supra note 150, at 639-40; see also 21 U.S.C. §§} 301 et seq. (1988).
172. Korwek, supra note 150, at 641-42.
173. Korwek, supra note 150, at 642.
174. Korwek, supra note 150, at 643.
175. Naumann, supra note 35, at 79-80.
176. Naumann, supra note 35, at 79-80. When the concept for a biotechnology review
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a centralized regulatory overseer for the developing applications of
biotechnology.
Another possible solution to the regulatory problems created by
genetic engineering is to elevate the status of the RAC and Human
Gene Therapy Subcommittee to a position in which they could over-
see all aspects of genetic engineering. This also creates some
problems, specifically for the medical applications of genetic engi-
neering, because the RAC and its subcommittee do not have a man-
date to address the ethical issues presented by either germ-line gene
therapy or enhancement genetic engineering. 177 Therefore, Adrienne
Naumann and other commentators have proposed the establishment
of a new 'super agency' or commission created in the mirror image
of the RAC, but with rule-making authority and the power to settle
interagency disputes. 78
Congress also became directly involved in the monitoring of bio-
technology in 1985 when it enacted legislation allowing for the crea-
tion of a Bioethics Board (BEB). 7 19 The BEB was modeled on the
Office of Technology Assessment and was comprised of twelve mem-
bers (six from each House of Congress - an equal number from
each party). 180 The function of the BEB was to provide Congress
with a continuing report on the ethical issues arising in the new field
of biotechnology.1 81 To aid the BEB in this task, the board was to
appoint a fourteen member Biomedical Ethics Advisory Committee
(BEAC) composed of four scientists, three doctors, five ethicists, and
two members of the public with an interest in biomedical ethics.
1 82
The promising potential of the BEB and BEAC all came to naught,
however, when the BEAC could not agree on a replacement for one
of the original members who had died before the first meeting.
83
Finally, Congress withdrew funding for both the BEB and BEAC in
1989 and, while the legislation is still on the books, no progress can
be made without funding.
184
board was first proposed in 1984, the board would have had the power to settle such disputes.
Under the original plan, the Biotechnology Science Board (BSB) would have had a structure
similar to the RAC and would have assumed many of the RAC's duties. Culliton, New Bi-
otech Review Board Planned, SCIENCE, Aug. 1985, at 736; see also 49 Fed. Reg. 50,905
(1984).
177. Areen and King, supra note 85, at 156.
178. Naumann, supra note 35, at 92-93; see also Culliton, supra note 176, at 736.
179. 42 U.S.C. § 275 (Supp. 1990). The BEB was approved by Congress over the veto
of President Reagan. Areen, supra note 29, at 171.
180. Areen and King, supra note 85, at 156.
181. 42 U.S.C. § 275(c)(1) (Supp. 1990).
182. 42 U.S.C. § 275(d) (Supp. 1990).
183. Areen and King, supra note 85, at 156.
184. Areen and King, supra note 85, at 157.
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The collapse of the BEB and BEAC in 1989, combined with the
inability of the BSCC to resolve interagency disputes, creates a seri-
ous obstacle to any unified policy of regulation for genetic engineer-
ing. Without a unified and consistent policy of regulation, the pro-
gress of genetic engineering, especially human gene therapy, may be
slowed by overregulation. It is essential for the development of
human gene therapy, therefore, that the government overcome the
obstacles that it has created and devise a unified system of regula-
tion. This could best be accomplished by Congress through the re-
funding of the BEB and BEAC. The BEB's function could be ex-
panded to include a review of the present regulatory system and the
development of options for streamlining the regulatory process. In
this way, the BEB could address both the ethical and regulatory
problems presented by the continued application of human gene
therapy. Such a committee would be endowed with the best elements
of the present RAC and the ability to resolve interagency disputes
that is lacking from the BSCC.
Present members of the RAC and members of the agencies cur-
rently regulating genetic manipulation would be ideal candidates for
positions on the BEAC. This would ensure that the decisions reached
by the BEAC would be the work of scientists, ethicists, and the gen-
eral public. In addition, the overall recommendations of the BEB
would carry the weight of a congressional committee report. Con-
gress could then enact the necessary legislation to implement the
BEB's recommendations. Once the new system of regulation was in
place, the BEB would continue to report to Congress on the progress
of the new system and the evolving concerns presented by the devel-
opment of human gene therapy. The end result of such a process
would be a unified system of regulation for gene therapy that would
avoid the problems presented by overlapping agency jurisdictions
and a permanent Congressional committee to oversee the regulatory
process and resolve any regulatory or ethical problems that arise in
the development of human gene therapy. Even if the BEB recom-
mended the continuation of the present system of regulation, the
BEB could still function as the information gathering and reporting
mechanism that Congress originally intended it to be. A functioning
BEB would ensure that Congress is kept well-informed about the dif-
ficult issues that will arise as human gene therapy develops. There-
fore, it is clear that Congress should redesign and re-fund the BEB
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and BEAC, for it is through the operation of these two boards that
the government will best be able to respond to the challenges of bio-
technology and human gene therapy.
Geoffrey Baskerville

